Moleculin Biotech Gains IRB Approval for Phase 3 Trial
Company Announcements

Moleculin Biotech Gains IRB Approval for Phase 3 Trial

Moleculin Biotech ( (MBRX) ) just unveiled an update.

Moleculin Biotech has received IRB approval for its pivotal Phase 3 MIRACLE trial, evaluating Annamycin with Cytarabine for treating relapsed or refractory acute myeloid leukemia (AML). The trial aims to accelerate approval, with enrollment starting in early 2025. This adaptive study could bring a crucial treatment option to AML patients, supported by positive data and FDA alignment.

Learn more about MBRX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMoleculin Biotech Unveils New Corporate Presentation
TheFlyMoleculin Biotech’s Phase 3 trial of Annamycin approved by Review Board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App